Diabetes Bites Newsletter: August 2017

/Diabetes Bites Newsletter: August 2017
Diabetes Bites Newsletter: August 2017 2017-08-16T22:13:58+00:00
diabetes bites newsletter

August 2017

1708, 2017

Could a Cancer Drug Preserve Some Beta Cell Function in Those Newly Diagnosed With Type 1 Diabetes

By | August 17th, 2017|

An early research study suggests that imatinib, which is a drug that suppresses the immune system , may help to preserve some beta cell function in people who are recently diagnosed with Type 1 diabetes. Imatinib, a tyrosine kinase inhibitor, is already approved for use in the treatment of Chronic Myelogenous Leukemia (CML) and several other cancers.

1608, 2017

Sneak Preview of New Type 1 Diabetes Research to be Presented at EASD Meeting

By | August 16th, 2017|

The European Association for the Study of Diabetes 2017 annual meeting will take place in Lisbon, Portugal from September 11-15, 2017. Some interesting research on Type 1 diabetes is on tap for the meeting, so here's a sneak preview!

1608, 2017

New Benefits Found With Liraglutide Use in Type 1 Diabetes Patients

By | August 16th, 2017|

Although it didn't work wonders for blood glucose (BG) levels, liraglutide improved anthropometric and metabolic parameters without causing an increase in hypoglycemia, according to the results of a clinical trial published in July in Diabetes, Obesity, and Metabolism.

1608, 2017

Glucose Concentrations and A1c Levels Vary by Race

By | August 16th, 2017|

Have you ever noticed when you look at your lab results, there's a measure of kidney function called eGFR that is reported for both non-African American, and for African American? That's because there are racial and ethnic differences in kidney function decline. When it comes to A1c levels, they are higher in black people than in white people. It is debatable if this is because of poorer glycemic control, or whether there are, in fact, differences between the races in the glycation of hemoglobin.

1608, 2017

Encouraging News About Sotagliflozin Use in Type 1 Diabetes

By | August 16th, 2017|

Sotagliflozin is a drug in development, under investigation by Lexicon Pharmaceuticals and Sanofi. It is a first-in-class, oral dual inhibitor of sodium-glucose cotransporter types 1 and 2 (SGLT1 and SGLT2).

1508, 2017

ViaCyte Starts Clinical Trial on PEC-Direct Islet Cell Replacement Therapy

By | August 15th, 2017|

Wouldn't it be great if a commercially-available product existed that was derived from stem cells and could effectively replace pancreatic islet cells to allow folks who can't produce endogenous insulin to actually start making it? ViaCyte is working on turning this into a reality someday.